ReviewFrontiers in immunology2024
Prognostic biomarkers for immunotherapy in esophageal cancer.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in patients with esophageal cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Intratumoral and peritumoral radiomics for preoperative prediction of pathological complete response to neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma.European journal of radiology open · 2026Article
- Response-adapted perioperative therapy for resectable esophageal cancer in the immunotherapy era: a narrative review.Journal of thoracic disease · 2026Review
- A Breg-associated lncRNA signature predicts prognosis and immune landscape in esophageal carcinoma.Translational cancer research · 2026Article
- A migration/invasion-related prognostic signature identifies and functionally validates SLC25A5 as a hub associated with spliceosome programs and invasive phenotypes in esophageal squamous cell carcinoma.Functional & integrative genomics · 2026Article
- Downregulation of PDCD10 mitigates the malignant biological behavior and increases the sensitivity of esophageal squamous cell carcinoma cells to radiotherapy by inhibiting the PI3K/AKT pathway.Histology and histopathology · 2026Article
- Integrative Multi-Omics and Pan-Cancer Analyses Identify CCL20 as a Prognostic Biomarker with Therapeutic Relevance in Esophageal Cancer.Biomedicines · 2026Article
- Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Prognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategies.Frontiers in immunology · 2026Article
- Analysis of risk factors for disease recurrence after endoscopic submucosal dissection of early esophageal cancer.World journal of gastrointestinal surgery · 2025Article
- A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or without immunotherapy.Journal of translational medicine · 2025Article
- A multimodal synergistic model for personalized neoadjuvant immunochemotherapy in esophageal cancer.Cell reports. Medicine · 2025Article
- Qige San regulates paclitaxel resistance in esophageal cancer by targeting ferroptosis.World journal of gastrointestinal oncology · 2025Article
- Multiplex imaging analysis of the tumor immune microenvironment for guiding precision immunotherapy.Frontiers in immunology · 2025Review
- Advancing immunotherapy for esophageal cancer: decoding the roles of PD-L1, TME, and tumor-intrinsic biomarkers.Frontiers in immunology · 2025Review
- Platelet Indices and ApoA1 as Predictive Markers in Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (EC), a common type of malignant tumor, ranks as the sixth highest contributor to cancer-related mortality worldwide. Due to the condition that most patients with EC are diagnosed at advanced or metastatic status, the efficacy of conventional treatments including surgery, chemotherapy and radiotherapy is limited, resulting in a dismal 5-year overall survival rate. In recent years, the application of immune checkpoint inhibitors (ICIs) has presented a novel therapeutic avenue for EC patients. Both ICIs monotherapy and immunotherapy combined with chemotherapy or chemoradiotherapy (CRT) have demonstrated marked benefits for patients with advanced EC. Adjuvant or neoadjuvant therapy incorporating immunotherapy has also demonstrated promising prospects in the context of perioperative treatment. Nonetheless, due to the variable response observed among patients undergoing immunotherapy, it is of vital importance to identify predictive biomarkers for patient stratification, to facilitate identification of subgroups who may derive greater benefits from immunotherapy. In this review, we summarize validated or potential biomarkers for immunotherapy in EC in three dimensions: tumor-cell-associated biomarkers, tumor-immune microenvironment (TIME)-associated factors, and host-associated biomarkers, so as to provide a theoretical foundation to inform tailored therapy for individuals diagnosed with EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.